Mark Sheptoff Financial Planning LLC Purchases Shares of 1,450 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mark Sheptoff Financial Planning LLC purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,450 shares of the specialty pharmaceutical company’s stock, valued at approximately $52,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $72,000. Venturi Wealth Management LLC purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $92,000. KBC Group NV increased its holdings in shares of Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $211,000.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Stock Up 1.1 %

NASDAQ SUPN opened at $33.05 on Wednesday. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 30.89 and a beta of 0.83. The company has a 50-day simple moving average of $35.49 and a two-hundred day simple moving average of $35.05. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Analysts Set New Price Targets

SUPN has been the subject of several research reports. StockNews.com lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.